After grabbing 200.0 shares, the institutional investor is now in possession of 200.0 shares of the Healthcare Company. The new investment brought the stake of investor firm to 0.00% having worth around $854.0. Moreover, Osaic Wealth, Inc. increased its share by 100.0 to have a control over 100.0 shares. And JPMorgan Asset Management raised its holdings to 14.0 shares by acquiring 14.0 shares or 0.00% of the stake.
Mainz Biomed N.V. (MYNZ) concluded trading on 09/13/23 at a closing price of $4.24, with 4.58 million shares of worth about $19.42 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -34.06% during that period and on Wednesday the price saw a gain of about 15.85%. Currently the company’s common shares owned by public are about 14.92M shares, out of which, 12.00M shares are available for trading.
A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 3 analysts are covering the MYNZ stock and their offered price forecasts bring an average price target of $9.00. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $11.00 and could fall to a lowest price of $7.00. The stock’s current price level is 52.89% above of average price target set by the analysts, while a rise to estimated low would result in gain of 39.43% for the stock. However, touching the estimated high of $11.00 would mean a gain of 61.45% for the stock.
The company recently came buying 0.0 shares which brought its stake up to 0.04% of the company’s outstanding shares.
Mainz Biomed N.V. (NASDAQ: MYNZ) started trading at $3.99, above $0.33 from concluding price of the previous day. However, the stock later moved at a day high price of 4.3700, or with a gain of 15.85%. Stock saw a price change of 32.50% in past 5 days and over the past one month there was a price change of 30.46%. Year-to-date (YTD), MYNZ shares are showing a performance of -40.28% which decreased to -52.68% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $2.84 but also hit the highest price of $9.61 during that period. The average intraday trading volume for Mainz Biomed N.V. shares is 32.69K. The stock is currently trading 34.15% above its 20-day simple moving average (SMA20), while that difference is up 10.75% for SMA50 and it goes to -24.62% lower than SMA200.
Morgan Stanley Smith Barney LLC acquired 200.0 shares of Mainz Biomed N.V. having value of about $854.0. Mainz Biomed N.V. (NASDAQ: MYNZ) currently have 14.92M outstanding shares and institutions hold larger chunk of about 0.20% of that. Holding of mutual funds in the company is about 0.04% while other institutional holders and individual stake holders have control over 0.08% and — of the stake respectively.
The stock has a current market capitalization of $66.86M and its 3Y-monthly beta is at 0.59. It has posted earnings per share of -$1.95 in the same period. It has Quick Ratio of 1.10 while making debt-to-equity ratio of 1.38. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for MYNZ, volatility over the week remained 9.87% while standing at 10.44% over the month.
Analysts are in expectations that Mainz Biomed N.V. (MYNZ) stock would likely to be making an EPS of $My Size, Inc. in the current quarter, while forecast for next quarter EPS is $1.35 and it is $Stocks for next year. For the current quarter EPS, analysts have given the company a lowest target $Mynaric AG – American Depositor which is $Blackrock MuniYield New York Qu at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of $MYYZ in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -122.60% while it is estimated to increase by 17.60% in next year.
Analysts at 3 brokerage firms have issued recommendations for the Mainz Biomed N.V. (MYNZ)’s stock and average of those rates the stock at a “Moderate Buy” and assign it a score of 2.00. Out of those 3 Wall Street analysts, 3 recommended a “Buy” rating, while 0 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by H.C. Wainwright on June 21, 2022 offering a Buy rating for the stock and assigned a target price of $25 to it.